NASDAQ:CDT CDT Equity (CDT) Stock Price, News & Analysis $1.50 -0.23 (-13.04%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$1.55 +0.05 (+3.33%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CDT Equity Stock (NASDAQ:CDT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CDT Equity alerts:Sign Up Key Stats Today's Range$1.50▼$1.7550-Day Range$1.50▼$17.1252-Week Range$1.50▼$1,200.00Volume61,754 shsAverage Volume39,026 shsMarket Capitalization$7.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited. Read More CDT Equity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreCDT MarketRank™: CDT Equity scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCDT Equity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCDT Equity has only been the subject of 1 research reports in the past 90 days.Read more about CDT Equity's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.68% of the float of CDT Equity has been sold short.Short Interest Ratio / Days to CoverCDT Equity has a short interest ratio ("days to cover") of 0.29, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CDT Equity has recently increased by 41.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCDT Equity does not currently pay a dividend.Dividend GrowthCDT Equity does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.39 News SentimentCDT Equity has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CDT Equity this week, compared to 2 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CDT Equity insiders have not sold or bought any company stock.Percentage Held by Insiders10.78% of the stock of CDT Equity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.29% of the stock of CDT Equity is held by institutions.Read more about CDT Equity's insider trading history. Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CDT Equity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDT Stock News HeadlinesCritical Review: Mannatech (NASDAQ:MTEX) versus CDT Equity (NASDAQ:CDT)May 17 at 3:27 AM | americanbankingnews.comCDT Equity Flags Delay in Quarterly FilingMay 15, 2026 | tipranks.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 19 at 1:00 AM | Paradigm Press (Ad)CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis MarketMay 7, 2026 | globenewswire.comCDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsMay 6, 2026 | globenewswire.comCDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven DiscoveryApril 16, 2026 | globenewswire.comWhat's Going On With CDT Equity Shares On Monday?April 13, 2026 | benzinga.comCDT Notes Sarborg Publication of PRISM Framework Expanding AIApril 7, 2026 | globenewswire.comSee More Headlines CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed this year? CDT Equity's stock was trading at $32.00 at the start of the year. Since then, CDT shares have decreased by 95.3% and is now trading at $1.50. How were CDT Equity's earnings last quarter? CDT Equity Inc. (NASDAQ:CDT) issued its earnings results on Thursday, August, 14th. The company reported ($1,092.00) EPS for the quarter. When did CDT Equity's stock split? Shares of CDT Equity reverse split on the morning of Friday, March 27th 2026.The 1-25 reverse split was announced on Wednesday, March 25th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of CDT Equity? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CDT Equity own? Based on aggregate information from My MarketBeat watchlists, some other companies that CDT Equity investors own include BIOLASE (BIOL), Dare Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Canoo (GOEV) and Jiuzi (JZXN). Company Calendar Last Earnings8/14/2025Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (23m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CDT's financial health is in the Red zone, according to TradeSmith. CDT has been in this zone for over 23 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($66,338.5469) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.22 million Net MarginsN/A Pretax MarginN/A Return on Equity-4,263.33% Return on Assets-529.91% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($77.82) per share Price / Book-0.02Miscellaneous Outstanding Shares4,858,000Free Float4,334,000Market Cap$7.29 million OptionableNot Optionable Beta1.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CDT) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CDT Equity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CDT Equity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
